Page 70 - 2020Taiwan Food and Drug Administration Annual Report

2019, the database stored 1,669 items of new narcotics ingredients and drug spectrogram and we
had created 336 of standard quality spectrograms and uploaded them to TFDA Urine and Drug
Abuse Report System (UDARS) for the narcotics inspection laboratory’s review and download.
,Q DGGLWLRQ D ÀLJKW PDVV VSHFWURPHWHU ZDV SXUFKDVHG DQG WKH GDWD RI LWHPV RI QDUFRWLFV DQG
controlled drugs have been created.

$FKLHYHPHQWV DQG %HQH¿WVFKLHYHPHQWV DQG %HQH¿WV
$

I. Facilitated international interaction on the control and inspection
technology of new psychoactive substances
TFDA cooperated with local health agencies, customs administration, police, prosecutors,

investigation agencies, and military police headquarters to share the current status of
international NPS, inspection technology and future challenges through conducting international
workshops, to understand the latest transnational crime patterns of narcotics and prevention
measures, as well as to improve our nation’s drug control strategy.

II. Improved the testing effectiveness of new abused drugs
The national laboratory actively improves the inspection and analysis capabilities and utilized
the liquid chromatography-tandem mass spectrometry. In the testing of narcotics cases that TFDA
assisted the prosecution, police, and investigation
authorities over the years, we successively tested positive
for the new abused drug ingredients of 25B-NBOMe and
Desoxy-D2PM, as well as successively tested positive for

the 2C-E, MPHP, and 6-Methoxy methylone ingredients
IRU WKH ¿UVW WLPH LQ WKH QDWLRQ ,Q WKH ZKLWH XQLGHQWL¿HG
crystal specimen sent by the police station for inspection
in 2019, the 2-Fluorodeschloroketamine was tested
positive (Figure 4-8). The 2-Fluorodeschloroketamine
is a arylcyclohexylamine compound and its appearance
and structure are similar to the ketamine ingredients.
To prevent the 2-Fluorodeschloroketamine from
circulating in the country, it had been included as the

Category three narcotics and the Schedule 3 controlled 'JHVSF cc*OHSFEJFOUT PG
drugs in November and December 2019, respectively, “ 'MVPSPEFTDIMPSPLFUBNJOF”
to effectively implement the anti-drug monitoring
capability.

68